Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 11/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19697171 | 0.88 | HTR1A (0.41) | HTR1ADRD2HTR2ASMYD3MMP12 | |
| SCHEMBL19697172 | 0.85 | HTR1A (0.42) | HTR1ADRD2HTR2ASMYD3MMP12 | |
| SCHEMBL430109 | 0.84 | HTR1A (0.40) | HTR1ADRD2HTR2ASMYD3MMP12 | |
| SCHEMBL16807806 | 0.81 | GABRA1 (0.33) | HTR1ADRD2HTR2ATRPV1 | |
| SCHEMBL16746147 | 0.79 | MMP12 (0.40) | HTR1ADRD2HTR2ASMYD3MMP12 | |
| SCHEMBL17476275 | 0.79 | SMYD3 (0.44) | SMYD3ADRB2ADRB1 | |
| SCHEMBL17476273 | 0.79 | SMYD3 (0.44) | SMYD3ADRB2ADRB1 | |
| SCHEMBL17476311 | 0.79 | SMYD3 (0.44) | SMYD3ADRB2ADRB1 | |
| SCHEMBL22521052 | 0.78 | SMYD3 (0.45) | HTR1ADRD2HTR2ASMYD3MMP12 | |
| SCHEMBL1851941 | 0.78 | CREBBP (0.58) | HTR1ADRD2SMYD3MMP12BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024119122-A1 | CDK INHIBITORS AND METHODS AND USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| WO-2023016434-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-02-16 | — | — | WO | disclosed |
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | disclosed |
| US-11000515-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-05-11 | — | — | US | disclosed |
| EP-3394056-B1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| WO-2020206137-A1 | CDK2/5 DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| US-20200061037-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
| US-20200048195-A1 | SUBSTITUTED PYRROLIDINE CARBOXAMIDE COMPOUNDS | Epizyme, Inc. | 2020-02-13 | — | — | US | disclosed |
| US-20070112015-A1 | Substituted dihydropyridines and methods of use | CHEMOCENTRYX, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| US-20060199810-A1 | Muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2006-09-07 | — | — | US | disclosed |
| US-20060199813-A1 | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2006-09-07 | — | — | US | disclosed |
| WO-2006068904-A1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| EP-1461318-B9 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARM INC (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20050209226-A1 | Neurodegenerative diseases, psychological disorders; e.g. 4-[3-(3a -Cyclopropylmethoxy-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-4H-benzo[1.4]oxazin-3-one | ACADIA PHARMACEUTICALS INC. | 2005-09-22 | — | — | US | disclosed |
| EP-1461318-B1 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARM INC (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1461318-A2 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | Acadia Pharmaceuticals Inc. (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20030176418-A1 | Tetrahydroquinoline analogues as muscarinic agonists | ACADIA PHARMACEUTICALS INC. | 2003-09-18 | — | — | US | disclosed |
| WO-2003057672-A2 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS | ACADIA PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199813-A1 | Tetrahydroquinoline analogues as muscarinic agonists | CHRM3, CHRM5, CHRM2 | HTR1A 175/4885DRD2 599/4885HTR2A 194/4885 |
| US-20050209226-A1 | Neurodegenerative diseases, psychological disorders; e.g. 4-[3-(3a -Cyclopropylmethoxy-8-azabicyclo[3.2.1]oct-8-yl)-2-methylpropyl]-4H-benzo[1.4]oxazin-3-one | CHRNA4, CHRNA2, CHRNA5 | HTR1A 31/4885DRD2 166/4885HTR2A 30/4885 |
| US-11000515-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | HTR1A 4855/4885DRD2 4877/4885HTR2A 4857/4885 |
| US-20030176418-A1 | Tetrahydroquinoline analogues as muscarinic agonists | CHRM3, CHRM5, CHRM2 | HTR1A 175/4885DRD2 599/4885HTR2A 194/4885 |
| US-20070112015-A1 | Substituted dihydropyridines and methods of use | C3AR1, C5AR1, C5AR2 | HTR1A 267/4885DRD2 735/4885HTR2A 302/4885 |
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | HTR1A 3743/4885DRD2 2319/4885HTR2A 2649/4885 |
| US-20060199810-A1 | Muscarinic agonists | CHRM3, CHRM5, CHRM2 | HTR1A 160/4885DRD2 623/4885HTR2A 205/4885 |
| US-20200048195-A1 | SUBSTITUTED PYRROLIDINE CARBOXAMIDE COMPOUNDS | SMYD3, SMYD2, SMURF2 | HTR1A 3308/4885DRD2 1113/4885HTR2A 1855/4885 |
| US-20200061037-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | HRAS, KRAS, NRAS | HTR1A 4855/4885DRD2 4877/4885HTR2A 4857/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | HTR1A 4794/4885DRD2 3526/4885HTR2A 4827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.